Sequenom (SQNM)
News
| 2:52 PM | Over-hyped: Verinata: 1,100 tests in initial weeks. $SQNM did > 10,000 commercial MaterniT21 PLUS test samples in 2012, as of May 12. by abubnic |
| 12:59 PM | $SQNM Alright! getting closer to my buy-in target of 3.7 Looking good from here. by Badbub |
| 12:48 PM | $sqnm this short squeeze is insane today! lol @ biotech by Prudentrader77 |
| 9:23 AM | Lol @biotech verinata numbers better than sequenoms first three months $sqnm #doyourresearchtool by Prudentrader77 |
| 8:56 AM | $SQNM competitor verinata with very weak test volume just PRd http://stks.co/42uL watch $SQNM for a shortsqueeze today by biotech |
| 2:32AM | 4 Highly Liquid Biotech Stocks With Bearish Short Trends |
| May 30 | The Dow Did Better Than Even These 2 Stocks Fool |
| May 30 | $SQNM nice bounce from Support by biotech |
| May 30 | Jeffries 2012 Global Healthcare Conf presentations, June 4-5 : $PBTH $AUXL $ONTY $NLNK $GEVA $MTD $SQNM $ARRY $THLD $SNTA $IMMU $IVC $AMLN by abubnic |
| May 30 | $SQNM holding up great compared to peers. by GArgondizza |
| May 29 | About That Stellar Data ... Fool |
| May 29 | Recently Published Independent Research Study Detects Gene Variation In Non-Small Cel... |
| May 29 | Sequenom Announces Participation at the Jefferies Global Healthcare Conference PR Newswire |
Profile
Exchange: NASDAQGM Sector: Healthcare Industry: Biotechnology
Sequenom, Inc. designs, develops, manufactures and markets innovative technology instrumentation. The company operates through two segments: Molecular Diagnostics and Genetic Analysis. The Molecular Diagnostics segment researches, develops and commercializes noninvasive molecular diagnostic tests for noninvasive womens' health-related and prenatal diagnostics, ophthalmology, oncology, infectious diseases, and other medical conditions disorders and diseases. The Genetic Analysis segment designs, markets and provides maintenance services for the proprietary MassARRAY system, comprised of hardware, software applications, consumable chips and reagents which are marketed to premier clinical research laboratories, bio-agriculture, bio-technology and pharmaceutical companies. The company was founded in 1994 and is headquartered in San Diego, California.
1 Year Total Return Performance
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Sequenom is down 51.64% over the last year vs S&P 500 Total Return up 0.88%, Coventry Health Care down 12.82%, and Osiris Therapeutics down 14.27%.
- SQNM Total Returns
- ^SPXTR Total Returns
- CVH Total Returns
- OSIR Total Returns
Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these SQNM related companies
Pro Strategies Featuring SQNM
Did Sequenom make it into our Pro Portfolio Strategies?
SQNM Charts
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Other SQNM Resources
- Company Website
- Wiki Page
- Investor Relations
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
- Technical Charts Chart.ly
- Trading Ideas Benzinga
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SQNM | 3.835 | -0.24 | -6.00% | 467.32M |
| SQM | 52.14 | -1.37 | -2.56% | 14.08B |
| SQI | 15.95 | +0.43 | +2.77% | 343.77M |
| SPYG | 61.81 | -0.24 | -0.39% | |
| SPY | 132.03 | +0.27 | +0.20% | |
| SPXU | 53.80 | -0.32 | -0.59% | |
| SPWR | 4.985 | -0.14 | -2.64% | 600.88M |
| SPW | 71.99 | -1.85 | -2.51% | 3.798B |
| SPU | 1.53 | +0.06 | +4.08% | 37.76M |
| SPTN | 16.77 | +0.12 | +0.72% | 380.79M |
